|
HAYWARD, CA, February 15, 2000 - Sepragen Corporation (OTC BB:
SPGNU, SPGNA, SPGNW) today announced the allowance of two new patent applications stemming from its core separation
technology, bringing the total number of patents on its platform technology and
related applications to 16.
The first of the latest two allowances relates to the Sepralac® Process for
extracting high value nutritional proteins from cheese whey
for use in infant formula and sports nutrition food and beverage products.
The second relates to the SepraDebitt® Process for removing bitterness and
acidity from citrus juices such as grapefruit and orange juice.
Vinit Saxena, Chairman and CEO of Sepragen commented, “Sepragen now has 14 patents
and 2 allowed patents to protect our platform separation technology and the
many processes and components that allow large scale applications and
commercialization.” He added, “We have recently begun commercialization of our Sepralac® Process through licensing arrangements
with two internationally recognized dairy suppliers and we are aggressively pursuing
agreements along all of our patented applications.”
Sepragen Corporation develops and markets technology along with equipment and supplies
for process chromatography applications. Sepragen has developed a number of patented
applications that provide large market opportunities in the food and beverage industry,
including debittering citrus juices, extracting isoflavone (plant estrogen) from soy, as
well as extracting proteins from whey. The company holds over 14 issued patents relating
to its core technology.
<
Back
The statements in this release that relate to future events
or performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|
